Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2022

01-01-2022 | Hypertension | Original Research

Blood Pressure Visit Intensification in Treatment (BP-Visit) Findings: a Pragmatic Stepped Wedge Cluster Randomized Trial

Authors: Kevin Fiscella, MD, MPH, Hua He, PhD, Mechelle Sanders, PhD, Andrea Cassells, MPH, Jennifer K. Carroll, MD, MPH, Stephen K. Williams, MD, Jerry Cornell, PhD, Tameir Holder, MPH, Chamanara Khalida, MD, MPH, Jonathan N. Tobin, PhD

Published in: Journal of General Internal Medicine | Issue 1/2022

Login to get access

Abstract

Background

Shortening time between office visits for patients with uncontrolled hypertension represents a potential strategy for improving blood pressure (BP).

Objective

We evaluated the impact of multimodal strategies on time between visits and on improvement in systolic BP (SBP) among patients with uncontrolled hypertension.

Design

We used a stepped-wedge cluster randomized controlled trial with three wedges involving 12 federally qualified health centers with three study periods: pre-intervention, intervention, and post-intervention.

Participants

Adult patients with diagnosed hypertension and two BPs ≥ 140/90 pre-randomization and at least one visit during post-randomization control period (N = 4277).

Intervention

The core intervention included three, clinician hypertension group-based trainings, monthly clinician feedback reports, and monthly meetings with practice champions to facilitate implementation.

Main Measures

The main measures were change in time between visits when BP was not controlled and change in SBP. A secondary planned outcome was changed in BP control among all hypertension patients in the practices.

Key Results

Median follow-up times were 34, 32, and 32 days and the mean SBPs were 142.0, 139.5, and 139.8 mmHg, respectively. In adjusted analyses, the intervention did not improve time to the next visit compared with control periods, HR = 1.01 (95% CI: 0.98, 1.04). SBP was reduced by 1.13 mmHg (95% CI: −2.10, −0.16), but was not maintained during follow-up. Hypertension control (< 140/90) in the practices improved by 5% during intervention (95% CI: 2.6%, 7.3%) and was sustained post-intervention 5.4% (95% CI: 2.6%, 8.2%).

Conclusions

The intervention failed to shorten follow-up time for patients with uncontrolled BP and showed very small, statistically significant improvements in SBP that were not sustained. However, the intervention showed statistically and clinically relevant improvement in hypertension control suggesting that the intervention affected clinician decision-making regarding BP control apart from visit frequency. Future practice initiatives should consider hypertension control as a primary outcome.

Clinical Trial

www.​ClinicalTrials.​gov Identifier: NCT02164331
Appendix
Available only for authorised users
Literature
2.
go back to reference Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. Ann Epidemiol. 2012;22(2):112-119.CrossRef Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. Ann Epidemiol. 2012;22(2):112-119.CrossRef
3.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.CrossRef Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.CrossRef
4.
go back to reference Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347(20):1585-1592.CrossRef Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347(20):1585-1592.CrossRef
5.
go back to reference James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.CrossRef James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.CrossRef
6.
go back to reference Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963.CrossRef Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963.CrossRef
7.
go back to reference Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7(6):327-332.CrossRef Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7(6):327-332.CrossRef
8.
go back to reference Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68-74.CrossRef Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68-74.CrossRef
9.
go back to reference Lichtenstein MJ, Sweetnam PM, Elwood PC. Visit frequency for controlled essential hypertension: general practitioners' opinions. J Fam Pract. 1986;23(4):331-336.PubMed Lichtenstein MJ, Sweetnam PM, Elwood PC. Visit frequency for controlled essential hypertension: general practitioners' opinions. J Fam Pract. 1986;23(4):331-336.PubMed
10.
go back to reference Ajzen I. Theory of planned behavior. Handb Theor Soc Psychol Vol One. 2011;1:438. Ajzen I. Theory of planned behavior. Handb Theor Soc Psychol Vol One. 2011;1:438.
11.
go back to reference Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381-2382.CrossRef Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381-2382.CrossRef
12.
go back to reference Pletcher MJ, Lo B, Grady D. Informed consent in randomized quality improvement trials: a critical barrier for learning health systems. JAMA Intern Med. 2014;174(5):668-670.CrossRef Pletcher MJ, Lo B, Grady D. Informed consent in randomized quality improvement trials: a critical barrier for learning health systems. JAMA Intern Med. 2014;174(5):668-670.CrossRef
13.
go back to reference Fiscella K, Ogedegbe G, He H, et al. Blood pressure visit intensification study in treatment: trial design. Am Heart J. 2015;170(6):1202-1210.CrossRef Fiscella K, Ogedegbe G, He H, et al. Blood pressure visit intensification study in treatment: trial design. Am Heart J. 2015;170(6):1202-1210.CrossRef
14.
go back to reference Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351-362.CrossRef Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351-362.CrossRef
15.
go back to reference Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. Brit Med J. 2015;350:h2147.CrossRef Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. Brit Med J. 2015;350:h2147.CrossRef
16.
go back to reference Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
17.
go back to reference Hicks LS, Sequist TD, Ayanian JZ, et al. Impact of computerized decision support on blood pressure management and control: a randomized controlled trial. J Gen Intern Med. 2008;23(4):429-441.CrossRef Hicks LS, Sequist TD, Ayanian JZ, et al. Impact of computerized decision support on blood pressure management and control: a randomized controlled trial. J Gen Intern Med. 2008;23(4):429-441.CrossRef
18.
go back to reference Ogedegbe G, Tobin JN, Fernandez S, et al. Counseling African Americans to control hypertension: cluster-randomized clinical trial main effects. Circulation. 2014;129(20):2044-2051.CrossRef Ogedegbe G, Tobin JN, Fernandez S, et al. Counseling African Americans to control hypertension: cluster-randomized clinical trial main effects. Circulation. 2014;129(20):2044-2051.CrossRef
19.
go back to reference Lopez PM, Divney A, Goldfeld K, et al. Feasibility and outcomes of an electronic health record intervention to improve hypertension management in immigrant-serving primary care practices. Med Care. 2019;57, Suppl 6, Suppl 2:S164-S171.CrossRef Lopez PM, Divney A, Goldfeld K, et al. Feasibility and outcomes of an electronic health record intervention to improve hypertension management in immigrant-serving primary care practices. Med Care. 2019;57, Suppl 6, Suppl 2:S164-S171.CrossRef
20.
go back to reference Kronish IM, Lynch AI, Oparil S, et al. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: findings from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2016;68(1):39-45.CrossRef Kronish IM, Lynch AI, Oparil S, et al. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: findings from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2016;68(1):39-45.CrossRef
21.
go back to reference Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ (Clinical research ed). 2016;354:i4098-i4098. Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ (Clinical research ed). 2016;354:i4098-i4098.
22.
go back to reference Kerse N, Buetow S, Mainous AG, 3rd, Young G, Coster G, Arroll B. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med. 2004;2(5):455-461.CrossRef Kerse N, Buetow S, Mainous AG, 3rd, Young G, Coster G, Arroll B. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med. 2004;2(5):455-461.CrossRef
23.
go back to reference Safran DG, Montgomery JE, Chang H, Murphy J, Rogers WH. Switching doctors: predictors of voluntary disenrollment from a primary physician's practice. [comment]. J Fam Pract. 2001;50(2):130-136.PubMed Safran DG, Montgomery JE, Chang H, Murphy J, Rogers WH. Switching doctors: predictors of voluntary disenrollment from a primary physician's practice. [comment]. J Fam Pract. 2001;50(2):130-136.PubMed
24.
go back to reference Stransky ML. Unmet needs for care and medications, cost as a reason for unmet needs, and unmet needs as a big problem, due to health-care provider (dis)continuity. J Patient Exp. 2018;5(4):258-266.CrossRef Stransky ML. Unmet needs for care and medications, cost as a reason for unmet needs, and unmet needs as a big problem, due to health-care provider (dis)continuity. J Patient Exp. 2018;5(4):258-266.CrossRef
25.
go back to reference Smith MA, Bartell JM. Changes in usual source of care and perceptions of health care access, quality, and use. Med Care. 2004;42(10):975-984.CrossRef Smith MA, Bartell JM. Changes in usual source of care and perceptions of health care access, quality, and use. Med Care. 2004;42(10):975-984.CrossRef
26.
go back to reference Lee RRS, Samsudin MI, Thirumoorthy T, Low LL, Kwan YH. Factors affecting follow-up non-attendance in patients with Type 2 diabetes mellitus and hypertension: a systematic review. Singapore Med J. 2019;60(5):216-223.CrossRef Lee RRS, Samsudin MI, Thirumoorthy T, Low LL, Kwan YH. Factors affecting follow-up non-attendance in patients with Type 2 diabetes mellitus and hypertension: a systematic review. Singapore Med J. 2019;60(5):216-223.CrossRef
27.
go back to reference Rowan CG, Flory J, Stempniewicz N, Cuddeback J, Brunelli SM. Stage 2 hypertension: predictors of failure to achieve blood pressure control and the impact of adding one additional antihypertensive class. Pharmacoepidemiol Drug Saf. 2015;24(11):1170-1179. Rowan CG, Flory J, Stempniewicz N, Cuddeback J, Brunelli SM. Stage 2 hypertension: predictors of failure to achieve blood pressure control and the impact of adding one additional antihypertensive class. Pharmacoepidemiol Drug Saf. 2015;24(11):1170-1179.
Metadata
Title
Blood Pressure Visit Intensification in Treatment (BP-Visit) Findings: a Pragmatic Stepped Wedge Cluster Randomized Trial
Authors
Kevin Fiscella, MD, MPH
Hua He, PhD
Mechelle Sanders, PhD
Andrea Cassells, MPH
Jennifer K. Carroll, MD, MPH
Stephen K. Williams, MD
Jerry Cornell, PhD
Tameir Holder, MPH
Chamanara Khalida, MD, MPH
Jonathan N. Tobin, PhD
Publication date
01-01-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 1/2022
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07016-9

Other articles of this Issue 1/2022

Journal of General Internal Medicine 1/2022 Go to the issue

Healing Arts

Delta Blues

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.